Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR Positive HER2 Negative Advanced Breast Cancer
Interventions: DRUG: Eribulin and Tucidinostat
Sponsor: Henan Cancer Hospital